The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Inclacumab was generally well tolerated in THRIVE-131
Phase 1 dosing is expected to finish by the end of 2025
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Subscribe To Our Newsletter & Stay Updated
